Cosentyx (secukinumab) is a medication used to treat autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. According to Drugs.com [2], Cosentyx falls under the FDA's Pregnancy Category B, which means that it is not expected to harm an unborn baby if used during pregnancy. However, the use of Cosentyx during pregnancy is only recommended if the potential benefits outweigh the potential risks.

The Drug Patent Watch [1] website provides information about the patent status of Cosentyx, but it does not provide information about adjusting the medication during pregnancy.

A study published in the Journal of Clinical Medicine [3] found that the use of Cosentyx during pregnancy did not appear to increase the risk of adverse outcomes for the mother or the baby. However, the study was limited by its small sample size and the lack of a control group.

In conclusion, while Cosentyx falls under the FDA's Pregnancy Category B, the use of this medication during pregnancy should only be considered if the potential benefits outweigh the potential risks. It is important to consult with a healthcare provider before adjusting any medication during pregnancy.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.drugs.com/pregnancy/secukinumab.html
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874874/